Skip to main content
Premium Trial:

Request an Annual Quote

Clontech, Tet Expand Licensing Agreement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Clontech Laboratories and Tet Systems said today they have expanded an existing licensing agreement to grant Clontech rights to develop, manufacture, and commercialize novel Tet products, including the Tet-On 3G Inducible Expression System.

In a statement, the two firms said that the new system offers highly inducible, sensitive control of gene expression and includes two novel components, including an improved transcriptional activator, which was developed by researchers at the Academic Medical Center at the University of Amsterdam, and a novel minimal Tet promoter developed at the University of Heidelberg.

The two firms said that the Tet-On 3G Inducible Expression System provides scientists greater control of gene expression regulation "due to lower expression in the non-induced state, even in transient transfection settings." It has 10-fold increased sensitivity for the inducing agent Doxycycline, expanding "the long-established benefits of dynamic transactivation, particularly for in vivo models," Clontech and Tet added.

Clontech will be launching a suite of the new systems, including promoters, fluorescent markers, and bicistronic systems on Aug. 2.

Terms of the amended agreement was not disclosed.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.